NCT02443116

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

A Phase 2, Randomized, Double-blind, Placebo-controlled Study With Additional Open-label, Single-blind and Placebo-controlled Cohorts to Assess the Safety, Tolerability, and Efficacy of NGM282 in Patients With Nonalcoholic Steatohepatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 254 (actual)
• Sponsor: NGM Biopharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.

Conditions

• Nonalcoholic Steatohepatitis (NASH)

Interventions

Type	Name	Description
BIOLOGICAL	NGM282
OTHER	Placebo

Timeline

• Start date: 2015-07-31
• Primary completion: 2019-12-06
• Completion: 2020-01-17
• First posted: 2015-05-13
• Last updated: 2025-07-23
• Results posted: 2025-06-26

Locations

22 sites across 3 countries: United States, Australia, Puerto Rico